#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=This study examined whether the combined administration of 6.0 g of glycine and 0.4 g of tryptophan suppressed the elevation in serum uric acid levels induced by purine ingestion and increased urinary uric acid excretion .
2-1	14-18	This	abstract[2]	new[2]	coref	8-1[45_2]
2-2	19-24	study	abstract[2]	new[2]	_	_
2-3	25-33	examined	_	_	_	_
2-4	34-41	whether	_	_	_	_
2-5	42-45	the	event[3]	new[3]	_	_
2-6	46-54	combined	event[3]	new[3]	_	_
2-7	55-69	administration	event[3]	new[3]	_	_
2-8	70-72	of	event[3]	new[3]	_	_
2-9	73-76	6.0	event[3]|substance[4]	new[3]|new[4]	_	_
2-10	77-78	g	event[3]|substance[4]	new[3]|new[4]	_	_
2-11	79-81	of	event[3]|substance[4]	new[3]|new[4]	_	_
2-12	82-89	glycine	event[3]|substance[4]|substance	new[3]|new[4]|new	coref	4-1[22_0]
2-13	90-93	and	event[3]	new[3]	_	_
2-14	94-97	0.4	event[3]|substance[6]	new[3]|new[6]	_	_
2-15	98-99	g	event[3]|substance[6]	new[3]|new[6]	_	_
2-16	100-102	of	event[3]|substance[6]	new[3]|new[6]	_	_
2-17	103-113	tryptophan	event[3]|substance[6]|substance	new[3]|new[6]|new	coref	4-4
2-18	114-124	suppressed	_	_	_	_
2-19	125-128	the	abstract[8]	new[8]	coref	9-15[56_8]
2-20	129-138	elevation	abstract[8]	new[8]	_	_
2-21	139-141	in	abstract[8]	new[8]	_	_
2-22	142-147	serum	abstract[8]|substance|abstract[12]	new[8]|new|new[12]	coref|coref	9-19|9-18[60_12]
2-23	148-152	uric	abstract[8]|abstract|substance[11]|abstract[12]	new[8]|new|new[11]|new[12]	coref|coref	2-33|2-32[16_11]
2-24	153-157	acid	abstract[8]|substance[11]|abstract[12]	new[8]|new[11]|new[12]	_	_
2-25	158-164	levels	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-26	165-172	induced	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-27	173-175	by	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-28	176-182	purine	abstract[8]|abstract[12]|substance|event[14]	new[8]|new[12]|new|new[14]	coref|coref	3-7[20_14]|9-25
2-29	183-192	ingestion	abstract[8]|abstract[12]|event[14]	new[8]|new[12]|new[14]	_	_
2-30	193-196	and	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-31	197-206	increased	abstract[8]|abstract[12]|event[17]|event	new[8]|new[12]|new[17]|new	coref|none|none	11-9[86_17]|2-31[0_261]|11-8
2-32	207-214	urinary	abstract[8]|abstract[12]|substance[16]|event[17]	new[8]|new[12]|giv[16]|new[17]	coref	3-2[18_16]
2-33	215-219	uric	abstract[8]|abstract[12]|abstract|substance[16]|event[17]	new[8]|new[12]|giv|giv[16]|new[17]	coref	9-20
2-34	220-224	acid	abstract[8]|abstract[12]|substance[16]|event[17]	new[8]|new[12]|giv[16]|new[17]	_	_
2-35	225-234	excretion	abstract[8]|abstract[12]|event[17]	new[8]|new[12]|new[17]	_	_
2-36	235-236	.	_	_	_	_

#Text=The amino acid doses used for single ingestion were based on those used in continual supplementation .
3-1	237-240	The	abstract[19]	new[19]	coref	5-5[28_19]
3-2	241-246	amino	substance[18]|abstract[19]	giv[18]|new[19]	coref	9-20[59_18]
3-3	247-251	acid	substance[18]|abstract[19]	giv[18]|new[19]	_	_
3-4	252-257	doses	abstract[19]	new[19]	_	_
3-5	258-262	used	abstract[19]	new[19]	_	_
3-6	263-266	for	abstract[19]	new[19]	_	_
3-7	267-273	single	abstract[19]|event[20]	new[19]|giv[20]	coref	9-25[62_20]
3-8	274-283	ingestion	abstract[19]|event[20]	new[19]|giv[20]	_	_
3-9	284-288	were	_	_	_	_
3-10	289-294	based	_	_	_	_
3-11	295-297	on	_	_	_	_
3-12	298-303	those	_	_	_	_
3-13	304-308	used	_	_	_	_
3-14	309-311	in	_	_	_	_
3-15	312-321	continual	substance[21]	new[21]	coref	8-7[50_21]
3-16	322-337	supplementation	substance[21]	new[21]	_	_
3-17	338-339	.	_	_	_	_

#Text=Both glycine and tryptophan are present in dietary proteins that are ingested in normal daily living .
4-1	340-344	Both	substance[22]|substance[23]	giv[22]|new[23]	coref|coref	5-3[27_22]|7-13[42_23]
4-2	345-352	glycine	substance[22]|substance[23]	giv[22]|new[23]	_	_
4-3	353-356	and	substance[23]	new[23]	_	_
4-4	357-367	tryptophan	substance[23]|substance	new[23]|giv	coref	7-15
4-5	368-371	are	_	_	_	_
4-6	372-379	present	_	_	_	_
4-7	380-382	in	_	_	_	_
4-8	383-390	dietary	substance[25]	new[25]	_	_
4-9	391-399	proteins	substance[25]	new[25]	_	_
4-10	400-404	that	substance[25]	new[25]	_	_
4-11	405-408	are	substance[25]	new[25]	_	_
4-12	409-417	ingested	substance[25]	new[25]	_	_
4-13	418-420	in	substance[25]	new[25]	_	_
4-14	421-427	normal	substance[25]|abstract[26]	new[25]|new[26]	_	_
4-15	428-433	daily	substance[25]|abstract[26]	new[25]|new[26]	_	_
4-16	434-440	living	substance[25]|abstract[26]	new[25]|new[26]	_	_
4-17	441-442	.	_	_	_	_

#Text=However , glycine at doses of up to 90 g per day administered over several weeks were reported no serious adverse effects .
5-1	443-450	However	_	_	_	_
5-2	451-452	,	_	_	_	_
5-3	453-460	glycine	substance[27]	giv[27]	coref	7-13[0_27]
5-4	461-463	at	substance[27]	giv[27]	_	_
5-5	464-469	doses	substance[27]|abstract[28]	giv[27]|giv[28]	_	_
5-6	470-472	of	substance[27]|abstract[28]	giv[27]|giv[28]	_	_
5-7	473-475	up	substance[27]|abstract[28]|abstract[29]	giv[27]|giv[28]|new[29]	_	_
5-8	476-478	to	substance[27]|abstract[28]|abstract[29]	giv[27]|giv[28]|new[29]	_	_
5-9	479-481	90	substance[27]|abstract[28]|abstract[29]	giv[27]|giv[28]|new[29]	_	_
5-10	482-483	g	substance[27]|abstract[28]|abstract[29]	giv[27]|giv[28]|new[29]	_	_
5-11	484-487	per	substance[27]|abstract[28]|abstract[29]	giv[27]|giv[28]|new[29]	_	_
5-12	488-491	day	substance[27]|abstract[28]|abstract[29]|time	giv[27]|giv[28]|new[29]|new	coref	6-12
5-13	492-504	administered	substance[27]|abstract[28]	giv[27]|giv[28]	_	_
5-14	505-509	over	substance[27]|abstract[28]	giv[27]|giv[28]	_	_
5-15	510-517	several	substance[27]|abstract[28]|time[31]	giv[27]|giv[28]|new[31]	_	_
5-16	518-523	weeks	substance[27]|abstract[28]|time[31]	giv[27]|giv[28]|new[31]	_	_
5-17	524-528	were	_	_	_	_
5-18	529-537	reported	_	_	_	_
5-19	538-540	no	abstract[32]	new[32]	coref	6-17[37_32]
5-20	541-548	serious	abstract[32]	new[32]	_	_
5-21	549-556	adverse	abstract[32]	new[32]	_	_
5-22	557-564	effects	abstract[32]	new[32]	_	_
5-23	565-566	.	_	_	_	_

#Text=The oral administration of up to 5.0 g of l-tryptophan per day did not lead to any adverse effects in young adult females .
6-1	567-570	The	event[33]	new[33]	_	_
6-2	571-575	oral	event[33]	new[33]	_	_
6-3	576-590	administration	event[33]	new[33]	_	_
6-4	591-593	of	event[33]	new[33]	_	_
6-5	594-596	up	event[33]|substance[34]	new[33]|new[34]	_	_
6-6	597-599	to	event[33]|substance[34]	new[33]|new[34]	_	_
6-7	600-603	5.0	event[33]|substance[34]	new[33]|new[34]	_	_
6-8	604-605	g	event[33]|substance[34]	new[33]|new[34]	_	_
6-9	606-608	of	event[33]|substance[34]	new[33]|new[34]	_	_
6-10	609-621	l-tryptophan	event[33]|substance[34]|person	new[33]|new[34]|new	_	_
6-11	622-625	per	event[33]	new[33]	_	_
6-12	626-629	day	event[33]|time	new[33]|giv	_	_
6-13	630-633	did	_	_	_	_
6-14	634-637	not	_	_	_	_
6-15	638-642	lead	_	_	_	_
6-16	643-645	to	_	_	_	_
6-17	646-649	any	abstract[37]	giv[37]	coref	7-3[39_37]
6-18	650-657	adverse	abstract[37]	giv[37]	_	_
6-19	658-665	effects	abstract[37]	giv[37]	_	_
6-20	666-668	in	abstract[37]	giv[37]	_	_
6-21	669-674	young	abstract[37]|person[38]	giv[37]|new[38]	_	_
6-22	675-680	adult	abstract[37]|person[38]	giv[37]|new[38]	_	_
6-23	681-688	females	abstract[37]|person[38]	giv[37]|new[38]	_	_
6-24	689-690	.	_	_	_	_

#Text=Therefore , no adverse effects were attributed to the combined administration of glycine and tryptophan in the current trial .
7-1	691-700	Therefore	_	_	_	_
7-2	701-702	,	_	_	_	_
7-3	703-705	no	abstract[39]	giv[39]	coref	19-21[159_39]
7-4	706-713	adverse	abstract[39]	giv[39]	_	_
7-5	714-721	effects	abstract[39]	giv[39]	_	_
7-6	722-726	were	_	_	_	_
7-7	727-737	attributed	_	_	_	_
7-8	738-740	to	_	_	_	_
7-9	741-744	the	organization[40]	new[40]	coref	9-6[52_40]
7-10	745-753	combined	organization[40]	new[40]	_	_
7-11	754-768	administration	organization[40]	new[40]	_	_
7-12	769-771	of	organization[40]	new[40]	_	_
7-13	772-779	glycine	organization[40]|substance|substance[42]	new[40]|giv|giv[42]	coref|coref	8-8|8-8[48_42]
7-14	780-783	and	organization[40]|substance[42]	new[40]|giv[42]	_	_
7-15	784-794	tryptophan	organization[40]|substance[42]|substance	new[40]|giv[42]|giv	coref	8-10
7-16	795-797	in	_	_	_	_
7-17	798-801	the	event[44]	new[44]	_	_
7-18	802-809	current	event[44]	new[44]	_	_
7-19	810-815	trial	event[44]	new[44]	_	_
7-20	816-817	.	_	_	_	_

#Text=This study confirmed the safety of combined glycine and tryptophan supplementation .
8-1	818-822	This	abstract[45]	giv[45]	coref	9-1[51_45]
8-2	823-828	study	abstract[45]	giv[45]	_	_
8-3	829-838	confirmed	_	_	_	_
8-4	839-842	the	abstract[46]	new[46]	_	_
8-5	843-849	safety	abstract[46]	new[46]	_	_
8-6	850-852	of	abstract[46]	new[46]	_	_
8-7	853-861	combined	abstract[46]|substance[50]	new[46]|giv[50]	coref	12-6[91_50]
8-8	862-869	glycine	abstract[46]|substance|substance[48]|substance[50]	new[46]|giv|giv[48]|giv[50]	coref|coref	9-10|9-10[54_48]
8-9	870-873	and	abstract[46]|substance[48]|substance[50]	new[46]|giv[48]|giv[50]	_	_
8-10	874-884	tryptophan	abstract[46]|substance[48]|substance|substance[50]	new[46]|giv[48]|giv|giv[50]	coref	9-12
8-11	885-900	supplementation	abstract[46]|substance[50]	new[46]|giv[50]	_	_
8-12	901-902	.	_	_	_	_

#Text=The current study demonstrated that the combined administration of glycine and tryptophan significantly suppressed the elevation in the serum uric acid levels caused by purine ingestion in healthy subjects .
9-1	903-906	The	abstract[51]	giv[51]	coref	11-18[89_51]
9-2	907-914	current	abstract[51]	giv[51]	_	_
9-3	915-920	study	abstract[51]	giv[51]	_	_
9-4	921-933	demonstrated	_	_	_	_
9-5	934-938	that	_	_	_	_
9-6	939-942	the	organization[52]	giv[52]	coref	10-4[67_52]
9-7	943-951	combined	organization[52]	giv[52]	_	_
9-8	952-966	administration	organization[52]	giv[52]	_	_
9-9	967-969	of	organization[52]	giv[52]	_	_
9-10	970-977	glycine	organization[52]|substance|substance[54]	giv[52]|giv|giv[54]	coref|coref	10-16|12-9[93_54]
9-11	978-981	and	organization[52]|substance[54]	giv[52]|giv[54]	_	_
9-12	982-992	tryptophan	organization[52]|substance[54]|substance	giv[52]|giv[54]|giv	coref	10-26
9-13	993-1006	significantly	_	_	_	_
9-14	1007-1017	suppressed	_	_	_	_
9-15	1018-1021	the	abstract[56]	giv[56]	coref	10-36[74_56]
9-16	1022-1031	elevation	abstract[56]	giv[56]	_	_
9-17	1032-1034	in	abstract[56]	giv[56]	_	_
9-18	1035-1038	the	abstract[56]|abstract[60]	giv[56]|giv[60]	coref	10-39[78_60]
9-19	1039-1044	serum	abstract[56]|substance|abstract[60]	giv[56]|giv|giv[60]	coref	10-40
9-20	1045-1049	uric	abstract[56]|abstract|substance[59]|abstract[60]	giv[56]|giv|giv[59]|giv[60]	coref|coref	10-6[66_59]|10-41
9-21	1050-1054	acid	abstract[56]|substance[59]|abstract[60]	giv[56]|giv[59]|giv[60]	_	_
9-22	1055-1061	levels	abstract[56]|abstract[60]	giv[56]|giv[60]	_	_
9-23	1062-1068	caused	abstract[56]|abstract[60]	giv[56]|giv[60]	_	_
9-24	1069-1071	by	abstract[56]|abstract[60]	giv[56]|giv[60]	_	_
9-25	1072-1078	purine	abstract[56]|abstract[60]|substance|event[62]	giv[56]|giv[60]|giv|giv[62]	coref	10-45[79_62]
9-26	1079-1088	ingestion	abstract[56]|abstract[60]|event[62]	giv[56]|giv[60]|giv[62]	_	_
9-27	1089-1091	in	abstract[56]|abstract[60]	giv[56]|giv[60]	_	_
9-28	1092-1099	healthy	abstract[56]|abstract[60]|animal[63]	giv[56]|giv[60]|new[63]	_	_
9-29	1100-1108	subjects	abstract[56]|abstract[60]|animal[63]	giv[56]|giv[60]|new[63]	_	_
9-30	1109-1110	.	_	_	_	_

#Text=The effect of the combined amino acid administration was stronger than that of the same glycine dose alone , indicating that a small amount of tryptophan provides an additional benefit to glycine alone in reducing the elevation in the serum uric acid levels after the ingestion of dietary purines .
10-1	1111-1114	The	abstract[64]	new[64]	_	_
10-2	1115-1121	effect	abstract[64]	new[64]	_	_
10-3	1122-1124	of	abstract[64]	new[64]	_	_
10-4	1125-1128	the	abstract[64]|organization[67]	new[64]|giv[67]	coref	19-26[162_67]
10-5	1129-1137	combined	abstract[64]|organization[67]	new[64]|giv[67]	_	_
10-6	1138-1143	amino	abstract[64]|object|substance[66]|organization[67]	new[64]|new|giv[66]|giv[67]	coref|coref	10-41[77_66]|18-4
10-7	1144-1148	acid	abstract[64]|substance[66]|organization[67]	new[64]|giv[66]|giv[67]	_	_
10-8	1149-1163	administration	abstract[64]|organization[67]	new[64]|giv[67]	_	_
10-9	1164-1167	was	_	_	_	_
10-10	1168-1176	stronger	_	_	_	_
10-11	1177-1181	than	_	_	_	_
10-12	1182-1186	that	_	_	_	_
10-13	1187-1189	of	_	_	_	_
10-14	1190-1193	the	substance[69]	new[69]	_	_
10-15	1194-1198	same	substance[69]	new[69]	_	_
10-16	1199-1206	glycine	substance|substance[69]	giv|new[69]	coref	10-32[73_0]
10-17	1207-1211	dose	substance[69]	new[69]	_	_
10-18	1212-1217	alone	substance[69]	new[69]	_	_
10-19	1218-1219	,	_	_	_	_
10-20	1220-1230	indicating	_	_	_	_
10-21	1231-1235	that	_	_	_	_
10-22	1236-1237	a	substance[70]	new[70]	_	_
10-23	1238-1243	small	substance[70]	new[70]	_	_
10-24	1244-1250	amount	substance[70]	new[70]	_	_
10-25	1251-1253	of	substance[70]	new[70]	_	_
10-26	1254-1264	tryptophan	substance[70]|substance	new[70]|giv	coref	12-11
10-27	1265-1273	provides	_	_	_	_
10-28	1274-1276	an	abstract[72]	new[72]	_	_
10-29	1277-1287	additional	abstract[72]	new[72]	_	_
10-30	1288-1295	benefit	abstract[72]	new[72]	_	_
10-31	1296-1298	to	abstract[72]	new[72]	_	_
10-32	1299-1306	glycine	abstract[72]|substance[73]	new[72]|giv[73]	coref	11-7[0_73]
10-33	1307-1312	alone	abstract[72]|substance[73]	new[72]|giv[73]	_	_
10-34	1313-1315	in	_	_	_	_
10-35	1316-1324	reducing	_	_	_	_
10-36	1325-1328	the	abstract[74]	giv[74]	coref	15-7[113_74]
10-37	1329-1338	elevation	abstract[74]	giv[74]	_	_
10-38	1339-1341	in	abstract[74]	giv[74]	_	_
10-39	1342-1345	the	abstract[74]|abstract[78]	giv[74]|giv[78]	coref	14-9[106_78]
10-40	1346-1351	serum	abstract[74]|substance|abstract[78]	giv[74]|giv|giv[78]	coref	27-3
10-41	1352-1356	uric	abstract[74]|abstract|substance[77]|abstract[78]	giv[74]|giv|giv[77]|giv[78]	coref|coref	11-10|11-10[85_77]
10-42	1357-1361	acid	abstract[74]|substance[77]|abstract[78]	giv[74]|giv[77]|giv[78]	_	_
10-43	1362-1368	levels	abstract[74]|abstract[78]	giv[74]|giv[78]	_	_
10-44	1369-1374	after	_	_	_	_
10-45	1375-1378	the	event[79]	giv[79]	_	_
10-46	1379-1388	ingestion	event[79]	giv[79]	_	_
10-47	1389-1391	of	event[79]	giv[79]	_	_
10-48	1392-1399	dietary	event[79]|substance[80]	giv[79]|new[80]	_	_
10-49	1400-1407	purines	event[79]|substance[80]	giv[79]|new[80]	_	_
10-50	1408-1409	.	_	_	_	_

#Text=In agreement with previous reports , glycine increased urinary uric acid excretion and enhanced urate clearance in the current study .
11-1	1410-1412	In	_	_	_	_
11-2	1413-1422	agreement	abstract[81]	new[81]	_	_
11-3	1423-1427	with	abstract[81]	new[81]	_	_
11-4	1428-1436	previous	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-5	1437-1444	reports	abstract[81]|abstract[82]	new[81]|new[82]	_	_
11-6	1445-1446	,	_	_	_	_
11-7	1447-1454	glycine	substance	giv	coref	12-9
11-8	1455-1464	increased	event	new	none	14-7
11-9	1465-1472	urinary	event[86]	giv[86]	coref	14-13[109_86]
11-10	1473-1477	uric	abstract|substance[85]|event[86]	giv|giv[85]|giv[86]	coref|coref	14-5|14-5[104_85]
11-11	1478-1482	acid	substance[85]|event[86]	giv[85]|giv[86]	_	_
11-12	1483-1492	excretion	event[86]	giv[86]	_	_
11-13	1493-1496	and	_	_	_	_
11-14	1497-1505	enhanced	_	_	_	_
11-15	1506-1511	urate	abstract|abstract[88]	new|new[88]	coref|coref	15-33|15-33[127_88]
11-16	1512-1521	clearance	abstract[88]	new[88]	_	_
11-17	1522-1524	in	_	_	_	_
11-18	1525-1528	the	abstract[89]	giv[89]	coref	24-2[193_89]
11-19	1529-1536	current	abstract[89]	giv[89]	_	_
11-20	1537-1542	study	abstract[89]	giv[89]	_	_
11-21	1543-1544	.	_	_	_	_

#Text=The authors previously reported that continual supplementation with glycine and tryptophan led to an increase in urinary pH .
12-1	1545-1548	The	person[90]	new[90]	_	_
12-2	1549-1556	authors	person[90]	new[90]	_	_
12-3	1557-1567	previously	_	_	_	_
12-4	1568-1576	reported	_	_	_	_
12-5	1577-1581	that	_	_	_	_
12-6	1582-1591	continual	substance[91]	giv[91]	coref	15-14[118_91]
12-7	1592-1607	supplementation	substance[91]	giv[91]	_	_
12-8	1608-1612	with	substance[91]	giv[91]	_	_
12-9	1613-1620	glycine	substance[91]|substance|substance[93]	giv[91]|giv|giv[93]	coref|coref	13-1|15-14[116_93]
12-10	1621-1624	and	substance[91]|substance[93]	giv[91]|giv[93]	_	_
12-11	1625-1635	tryptophan	substance[91]|substance[93]|substance	giv[91]|giv[93]|giv	coref	15-16
12-12	1636-1639	led	_	_	_	_
12-13	1640-1642	to	_	_	_	_
12-14	1643-1645	an	event[95]	new[95]	_	_
12-15	1646-1654	increase	event[95]	new[95]	_	_
12-16	1655-1657	in	event[95]	new[95]	_	_
12-17	1658-1665	urinary	event[95]|abstract[96]	new[95]|new[96]	coref	14-10[0_96]
12-18	1666-1668	pH	event[95]|abstract[96]	new[95]|new[96]	_	_
12-19	1669-1670	.	_	_	_	_

#Text=Glycine exhibits a buffering action and it is often used as an antacid .
13-1	1671-1678	Glycine	substance	giv	coref	15-14
13-2	1679-1687	exhibits	_	_	_	_
13-3	1688-1689	a	event[98]	new[98]	ana	13-7[0_98]
13-4	1690-1699	buffering	event[98]	new[98]	_	_
13-5	1700-1706	action	event[98]	new[98]	_	_
13-6	1707-1710	and	_	_	_	_
13-7	1711-1713	it	event	giv	coref	22-6[185_0]
13-8	1714-1716	is	_	_	_	_
13-9	1717-1722	often	_	_	_	_
13-10	1723-1727	used	_	_	_	_
13-11	1728-1730	as	_	_	_	_
13-12	1731-1733	an	abstract[100]	new[100]	_	_
13-13	1734-1741	antacid	abstract[100]	new[100]	_	_
13-14	1742-1743	.	_	_	_	_

#Text=The water solubility of uric acid increases with increasing pH levels and uric acid excretion is more favorable in alkaline urine than in acidic urine .
14-1	1744-1747	The	substance[102]	new[102]	_	_
14-2	1748-1753	water	substance|substance[102]	new|new[102]	_	_
14-3	1754-1764	solubility	substance[102]	new[102]	_	_
14-4	1765-1767	of	substance[102]	new[102]	_	_
14-5	1768-1772	uric	substance[102]|abstract|substance[104]	new[102]|giv|giv[104]	coref|coref	14-13|14-13[108_104]
14-6	1773-1777	acid	substance[102]|substance[104]	new[102]|giv[104]	_	_
14-7	1778-1787	increases	event	new	none	17-5
14-8	1788-1792	with	_	_	_	_
14-9	1793-1803	increasing	abstract[106]	giv[106]	coref	27-1[222_106]
14-10	1804-1806	pH	abstract|abstract[106]	giv|giv[106]	coref	15-10[114_0]
14-11	1807-1813	levels	abstract[106]	giv[106]	_	_
14-12	1814-1817	and	_	_	_	_
14-13	1818-1822	uric	abstract|substance[108]|event[109]	giv|giv[108]|giv[109]	ana|coref|coref	15-3[0_109]|15-23|15-22[121_108]
14-14	1823-1827	acid	substance[108]|event[109]	giv[108]|giv[109]	_	_
14-15	1828-1837	excretion	event[109]	giv[109]	_	_
14-16	1838-1840	is	_	_	_	_
14-17	1841-1845	more	_	_	_	_
14-18	1846-1855	favorable	_	_	_	_
14-19	1856-1858	in	_	_	_	_
14-20	1859-1867	alkaline	substance[110]	new[110]	_	_
14-21	1868-1873	urine	substance[110]	new[110]	_	_
14-22	1874-1878	than	_	_	_	_
14-23	1879-1881	in	_	_	_	_
14-24	1882-1888	acidic	substance[111]	new[111]	_	_
14-25	1889-1894	urine	substance[111]	new[111]	_	_
14-26	1895-1896	.	_	_	_	_

#Text=Therefore , it is possible that the elevation in urinary pH caused by glycine and tryptophan supplementation enhanced the solubility of urinary uric acid , thereby elevating urinary uric acid excretion and urate clearance .
15-1	1897-1906	Therefore	_	_	_	_
15-2	1907-1908	,	_	_	_	_
15-3	1909-1911	it	event	giv	coref	15-28[124_0]
15-4	1912-1914	is	_	_	_	_
15-5	1915-1923	possible	_	_	_	_
15-6	1924-1928	that	_	_	_	_
15-7	1929-1932	the	abstract[113]	giv[113]	coref	19-4[155_113]
15-8	1933-1942	elevation	abstract[113]	giv[113]	_	_
15-9	1943-1945	in	abstract[113]	giv[113]	_	_
15-10	1946-1953	urinary	abstract[113]|abstract[114]	giv[113]|giv[114]	coref	17-6[139_114]
15-11	1954-1956	pH	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-12	1957-1963	caused	abstract[113]	giv[113]	_	_
15-13	1964-1966	by	abstract[113]	giv[113]	_	_
15-14	1967-1974	glycine	abstract[113]|substance|substance[116]|substance[118]	giv[113]|giv|giv[116]|giv[118]	coref|coref|coref	19-14|24-6[194_118]|27-6[224_116]
15-15	1975-1978	and	abstract[113]|substance[116]|substance[118]	giv[113]|giv[116]|giv[118]	_	_
15-16	1979-1989	tryptophan	abstract[113]|substance[116]|substance|substance[118]	giv[113]|giv[116]|giv|giv[118]	coref	24-9
15-17	1990-2005	supplementation	abstract[113]|substance[118]	giv[113]|giv[118]	_	_
15-18	2006-2014	enhanced	_	_	_	_
15-19	2015-2018	the	substance[119]	new[119]	_	_
15-20	2019-2029	solubility	substance[119]	new[119]	_	_
15-21	2030-2032	of	substance[119]	new[119]	_	_
15-22	2033-2040	urinary	substance[119]|substance[121]	new[119]|giv[121]	coref	15-29[123_121]
15-23	2041-2045	uric	substance[119]|abstract|substance[121]	new[119]|giv|giv[121]	coref	15-29
15-24	2046-2050	acid	substance[119]|substance[121]	new[119]|giv[121]	_	_
15-25	2051-2052	,	_	_	_	_
15-26	2053-2060	thereby	_	_	_	_
15-27	2061-2070	elevating	_	_	_	_
15-28	2071-2078	urinary	event[124]|abstract[125]	giv[124]|new[125]	coref|coref	19-29[165_124]|19-29[166_125]
15-29	2079-2083	uric	abstract|substance[123]|event[124]|abstract[125]	giv|giv[123]|giv[124]|new[125]	coref|coref	17-11[141_123]|17-27
15-30	2084-2088	acid	substance[123]|event[124]|abstract[125]	giv[123]|giv[124]|new[125]	_	_
15-31	2089-2098	excretion	event[124]|abstract[125]	giv[124]|new[125]	_	_
15-32	2099-2102	and	abstract[125]	new[125]	_	_
15-33	2103-2108	urate	abstract[125]|abstract|abstract[127]	new[125]|giv|giv[127]	coref|coref	19-33|19-33[168_127]
15-34	2109-2118	clearance	abstract[125]|abstract[127]	new[125]|giv[127]	_	_
15-35	2119-2120	.	_	_	_	_

#Text=Previous studies provide physiological , physicochemical and clinical validation for the use of citrate salt in the treatment of some types of lithiasis .
16-1	2121-2129	Previous	abstract[128]	new[128]	coref	23-1[189_128]
16-2	2130-2137	studies	abstract[128]	new[128]	_	_
16-3	2138-2145	provide	_	_	_	_
16-4	2146-2159	physiological	event[129]	new[129]	_	_
16-5	2160-2161	,	event[129]	new[129]	_	_
16-6	2162-2177	physicochemical	event[129]	new[129]	_	_
16-7	2178-2181	and	event[129]	new[129]	_	_
16-8	2182-2190	clinical	event[129]	new[129]	_	_
16-9	2191-2201	validation	event[129]	new[129]	_	_
16-10	2202-2205	for	event[129]	new[129]	_	_
16-11	2206-2209	the	event[129]|event[130]	new[129]|new[130]	_	_
16-12	2210-2213	use	event[129]|event[130]	new[129]|new[130]	_	_
16-13	2214-2216	of	event[129]|event[130]	new[129]|new[130]	_	_
16-14	2217-2224	citrate	event[129]|event[130]|person|substance[132]	new[129]|new[130]|new|new[132]	coref	17-1
16-15	2225-2229	salt	event[129]|event[130]|substance[132]	new[129]|new[130]|new[132]	_	_
16-16	2230-2232	in	event[129]|event[130]|substance[132]	new[129]|new[130]|new[132]	_	_
16-17	2233-2236	the	event[129]|event[130]|substance[132]|event[133]	new[129]|new[130]|new[132]|new[133]	coref	17-1[138_133]
16-18	2237-2246	treatment	event[129]|event[130]|substance[132]|event[133]	new[129]|new[130]|new[132]|new[133]	_	_
16-19	2247-2249	of	event[129]|event[130]|substance[132]|event[133]	new[129]|new[130]|new[132]|new[133]	_	_
16-20	2250-2254	some	event[129]|event[130]|substance[132]|event[133]|place[134]	new[129]|new[130]|new[132]|new[133]|new[134]	_	_
16-21	2255-2260	types	event[129]|event[130]|substance[132]|event[133]|place[134]	new[129]|new[130]|new[132]|new[133]|new[134]	_	_
16-22	2261-2263	of	event[129]|event[130]|substance[132]|event[133]|place[134]	new[129]|new[130]|new[132]|new[133]|new[134]	_	_
16-23	2264-2273	lithiasis	event[129]|event[130]|substance[132]|event[133]|place[134]|abstract	new[129]|new[130]|new[132]|new[133]|new[134]|new	coref	17-11[142_0]
16-24	2274-2275	.	_	_	_	_

#Text=Citrate salts treatment substantially increased urinary pH in patients with uric acid lithiasis , however , there was no significant change in the amount of urinary uric acid .
17-1	2276-2283	Citrate	person|substance[137]|event[138]	giv|new[137]|giv[138]	coref|coref	18-10|18-10[151_137]
17-2	2284-2289	salts	substance[137]|event[138]	new[137]|giv[138]	_	_
17-3	2290-2299	treatment	event[138]	giv[138]	_	_
17-4	2300-2313	substantially	_	_	_	_
17-5	2314-2323	increased	event	new	coref	29-1[240_0]
17-6	2324-2331	urinary	abstract[139]	giv[139]	coref	19-7[156_139]
17-7	2332-2334	pH	abstract[139]	giv[139]	_	_
17-8	2335-2337	in	_	_	_	_
17-9	2338-2346	patients	person[140]	new[140]	_	_
17-10	2347-2351	with	person[140]	new[140]	_	_
17-11	2352-2356	uric	person[140]|substance[141]|abstract[142]	new[140]|giv[141]|giv[142]	coref	17-26[146_141]
17-12	2357-2361	acid	person[140]|substance[141]|abstract[142]	new[140]|giv[141]|giv[142]	_	_
17-13	2362-2371	lithiasis	person[140]|abstract[142]	new[140]|giv[142]	_	_
17-14	2372-2373	,	_	_	_	_
17-15	2374-2381	however	_	_	_	_
17-16	2382-2383	,	_	_	_	_
17-17	2384-2389	there	_	_	_	_
17-18	2390-2393	was	_	_	_	_
17-19	2394-2396	no	abstract[143]	new[143]	_	_
17-20	2397-2408	significant	abstract[143]	new[143]	_	_
17-21	2409-2415	change	abstract[143]	new[143]	_	_
17-22	2416-2418	in	abstract[143]	new[143]	_	_
17-23	2419-2422	the	abstract[143]|abstract[144]	new[143]|new[144]	_	_
17-24	2423-2429	amount	abstract[143]|abstract[144]	new[143]|new[144]	_	_
17-25	2430-2432	of	abstract[143]|abstract[144]	new[143]|new[144]	_	_
17-26	2433-2440	urinary	abstract[143]|abstract[144]|substance[146]	new[143]|new[144]|giv[146]	coref	19-29[164_146]
17-27	2441-2445	uric	abstract[143]|abstract[144]|abstract|substance[146]	new[143]|new[144]|giv|giv[146]	coref	19-29
17-28	2446-2450	acid	abstract[143]|abstract[144]|substance[146]	new[143]|new[144]|giv[146]	_	_
17-29	2451-2452	.	_	_	_	_

#Text=The mixture of amino acids might be superior to citrate salts in the prevention or treatment of hyperuricemia .
18-1	2453-2456	The	substance[147]	new[147]	_	_
18-2	2457-2464	mixture	substance[147]	new[147]	_	_
18-3	2465-2467	of	substance[147]	new[147]	_	_
18-4	2468-2473	amino	substance[147]|object|substance[149]	new[147]|giv|new[149]	coref|coref	27-25|27-24[230_149]
18-5	2474-2479	acids	substance[147]|substance[149]	new[147]|new[149]	_	_
18-6	2480-2485	might	_	_	_	_
18-7	2486-2488	be	_	_	_	_
18-8	2489-2497	superior	_	_	_	_
18-9	2498-2500	to	_	_	_	_
18-10	2501-2508	citrate	person|substance[151]	giv|giv[151]	_	_
18-11	2509-2514	salts	substance[151]	giv[151]	_	_
18-12	2515-2517	in	_	_	_	_
18-13	2518-2521	the	abstract[152]	new[152]	_	_
18-14	2522-2532	prevention	abstract[152]	new[152]	_	_
18-15	2533-2535	or	_	_	_	_
18-16	2536-2545	treatment	abstract[153]	new[153]	_	_
18-17	2546-2548	of	abstract[153]	new[153]	_	_
18-18	2549-2562	hyperuricemia	abstract[153]|abstract	new[153]|new	_	_
18-19	2563-2564	.	_	_	_	_

#Text=Herein , although the elevation of urinary pH induced by the ingestion of glycine alone was not significant compared with the effects of placebo , glycine administration enhanced uric acid excretion and urate clearance , raising the possibility of other mechanisms .
19-1	2565-2571	Herein	_	_	_	_
19-2	2572-2573	,	_	_	_	_
19-3	2574-2582	although	_	_	_	_
19-4	2583-2586	the	abstract[155]	giv[155]	coref	25-21[210_155]
19-5	2587-2596	elevation	abstract[155]	giv[155]	_	_
19-6	2597-2599	of	abstract[155]	giv[155]	_	_
19-7	2600-2607	urinary	abstract[155]|abstract[156]	giv[155]|giv[156]	coref	24-15[197_156]
19-8	2608-2610	pH	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
19-9	2611-2618	induced	abstract[155]	giv[155]	_	_
19-10	2619-2621	by	abstract[155]	giv[155]	_	_
19-11	2622-2625	the	abstract[155]|event[157]	giv[155]|new[157]	coref	27-15[227_157]
19-12	2626-2635	ingestion	abstract[155]|event[157]	giv[155]|new[157]	_	_
19-13	2636-2638	of	abstract[155]|event[157]	giv[155]|new[157]	_	_
19-14	2639-2646	glycine	abstract[155]|event[157]|substance	giv[155]|new[157]|giv	coref	19-26
19-15	2647-2652	alone	abstract[155]|event[157]	giv[155]|new[157]	_	_
19-16	2653-2656	was	_	_	_	_
19-17	2657-2660	not	_	_	_	_
19-18	2661-2672	significant	_	_	_	_
19-19	2673-2681	compared	_	_	_	_
19-20	2682-2686	with	_	_	_	_
19-21	2687-2690	the	abstract[159]	giv[159]	_	_
19-22	2691-2698	effects	abstract[159]	giv[159]	_	_
19-23	2699-2701	of	abstract[159]	giv[159]	_	_
19-24	2702-2709	placebo	abstract[159]|substance	giv[159]|new	_	_
19-25	2710-2711	,	_	_	_	_
19-26	2712-2719	glycine	substance|organization[162]	giv|giv[162]	coref	22-3
19-27	2720-2734	administration	organization[162]	giv[162]	_	_
19-28	2735-2743	enhanced	_	_	_	_
19-29	2744-2748	uric	abstract|substance[164]|event[165]|abstract[166]	giv|giv[164]|giv[165]|giv[166]	coref|coref|coref|coref	22-10|22-10[187_164]|24-18[200_165]|29-4[243_166]
19-30	2749-2753	acid	substance[164]|event[165]|abstract[166]	giv[164]|giv[165]|giv[166]	_	_
19-31	2754-2763	excretion	event[165]|abstract[166]	giv[165]|giv[166]	_	_
19-32	2764-2767	and	abstract[166]	giv[166]	_	_
19-33	2768-2773	urate	abstract[166]|abstract|abstract[168]	giv[166]|giv|giv[168]	coref|coref	20-1|24-23[202_168]
19-34	2774-2783	clearance	abstract[166]|abstract[168]	giv[166]|giv[168]	_	_
19-35	2784-2785	,	_	_	_	_
19-36	2786-2793	raising	_	_	_	_
19-37	2794-2797	the	abstract[169]	new[169]	_	_
19-38	2798-2809	possibility	abstract[169]	new[169]	_	_
19-39	2810-2812	of	abstract[169]	new[169]	_	_
19-40	2813-2818	other	abstract[169]|abstract[170]	new[169]|new[170]	_	_
19-41	2819-2829	mechanisms	abstract[169]|abstract[170]	new[169]|new[170]	_	_
19-42	2830-2831	.	_	_	_	_

#Text=Urate transporter 1 ( URAT1 ) , a primary reabsorptive urate transporter that is targeted by pyrazinamide , reportedly disables glycine-induced uricosuria .
20-1	2832-2837	Urate	abstract|abstract[172]	giv|new[172]	appos|coref	20-5[0_172]|20-11
20-2	2838-2849	transporter	abstract[172]	new[172]	_	_
20-3	2850-2851	1	abstract[172]	new[172]	_	_
20-4	2852-2853	(	_	_	_	_
20-5	2854-2859	URAT1	abstract	giv	appos	20-8[175_0]
20-6	2860-2861	)	_	_	_	_
20-7	2862-2863	,	_	_	_	_
20-8	2864-2865	a	abstract[175]	giv[175]	coref	22-17[0_175]
20-9	2866-2873	primary	abstract[175]	giv[175]	_	_
20-10	2874-2886	reabsorptive	abstract[175]	giv[175]	_	_
20-11	2887-2892	urate	abstract|abstract[175]	giv|giv[175]	coref	21-6
20-12	2893-2904	transporter	abstract[175]	giv[175]	_	_
20-13	2905-2909	that	abstract[175]	giv[175]	_	_
20-14	2910-2912	is	abstract[175]	giv[175]	_	_
20-15	2913-2921	targeted	abstract[175]	giv[175]	_	_
20-16	2922-2924	by	abstract[175]	giv[175]	_	_
20-17	2925-2937	pyrazinamide	abstract[175]|substance	giv[175]|new	coref	21-1
20-18	2938-2939	,	_	_	_	_
20-19	2940-2950	reportedly	_	_	_	_
20-20	2951-2959	disables	_	_	_	_
20-21	2960-2975	glycine-induced	place[177]	new[177]	_	_
20-22	2976-2986	uricosuria	place[177]	new[177]	_	_
20-23	2987-2988	.	_	_	_	_

#Text=Pyrazinamide may reflect the enhanced urate reabsorption following the exchange of its active metabolite .
21-1	2989-3001	Pyrazinamide	substance	giv	ana	21-12
21-2	3002-3005	may	_	_	_	_
21-3	3006-3013	reflect	_	_	_	_
21-4	3014-3017	the	event[180]	new[180]	_	_
21-5	3018-3026	enhanced	event[180]	new[180]	_	_
21-6	3027-3032	urate	abstract|event[180]	giv|new[180]	coref	24-23
21-7	3033-3045	reabsorption	event[180]	new[180]	_	_
21-8	3046-3055	following	_	_	_	_
21-9	3056-3059	the	event[181]	new[181]	_	_
21-10	3060-3068	exchange	event[181]	new[181]	_	_
21-11	3069-3071	of	event[181]	new[181]	_	_
21-12	3072-3075	its	event[181]|substance|substance[183]	new[181]|giv|new[183]	_	_
21-13	3076-3082	active	event[181]|substance[183]	new[181]|new[183]	_	_
21-14	3083-3093	metabolite	event[181]|substance[183]	new[181]|new[183]	_	_
21-15	3094-3095	.	_	_	_	_

#Text=Thus , glycine may inhibit the reabsorptive action of uric acid , which is induced by URAT1 .
22-1	3096-3100	Thus	_	_	_	_
22-2	3101-3102	,	_	_	_	_
22-3	3103-3110	glycine	substance	giv	coref	23-10
22-4	3111-3114	may	_	_	_	_
22-5	3115-3122	inhibit	_	_	_	_
22-6	3123-3126	the	event[185]	giv[185]	_	_
22-7	3127-3139	reabsorptive	event[185]	giv[185]	_	_
22-8	3140-3146	action	event[185]	giv[185]	_	_
22-9	3147-3149	of	event[185]	giv[185]	_	_
22-10	3150-3154	uric	event[185]|abstract|substance[187]	giv[185]|giv|giv[187]	coref|coref	24-19|24-19[199_187]
22-11	3155-3159	acid	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-12	3160-3161	,	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-13	3162-3167	which	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-14	3168-3170	is	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-15	3171-3178	induced	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-16	3179-3181	by	event[185]|substance[187]	giv[185]|giv[187]	_	_
22-17	3182-3187	URAT1	event[185]|substance[187]|abstract	giv[185]|giv[187]|giv	coref	23-12
22-18	3188-3189	.	_	_	_	_

#Text=Further studies are needed to elucidate the action of glycine on URAT1 .
23-1	3190-3197	Further	abstract[189]	giv[189]	coref	32-1[272_189]
23-2	3198-3205	studies	abstract[189]	giv[189]	_	_
23-3	3206-3209	are	_	_	_	_
23-4	3210-3216	needed	_	_	_	_
23-5	3217-3219	to	_	_	_	_
23-6	3220-3229	elucidate	_	_	_	_
23-7	3230-3233	the	event[190]	new[190]	coref	25-17[207_190]
23-8	3234-3240	action	event[190]	new[190]	_	_
23-9	3241-3243	of	event[190]	new[190]	_	_
23-10	3244-3251	glycine	event[190]|substance	new[190]|giv	coref	25-31
23-11	3252-3254	on	event[190]	new[190]	_	_
23-12	3255-3260	URAT1	event[190]|abstract	new[190]|giv	coref	25-7
23-13	3261-3262	.	_	_	_	_

#Text=In the current study , the supplementation with tryptophan alone had no influence on urinary pH , urinary uric acid excretion or urate clearance .
24-1	3263-3265	In	_	_	_	_
24-2	3266-3269	the	abstract[193]	giv[193]	coref	33-5[282_193]
24-3	3270-3277	current	abstract[193]	giv[193]	_	_
24-4	3278-3283	study	abstract[193]	giv[193]	_	_
24-5	3284-3285	,	_	_	_	_
24-6	3286-3289	the	substance[194]	giv[194]	ana	25-25[0_194]
24-7	3290-3305	supplementation	substance[194]	giv[194]	_	_
24-8	3306-3310	with	substance[194]	giv[194]	_	_
24-9	3311-3321	tryptophan	substance[194]|substance	giv[194]|giv	coref	25-5
24-10	3322-3327	alone	_	_	_	_
24-11	3328-3331	had	_	_	_	_
24-12	3332-3334	no	abstract[196]	new[196]	coref	25-25[212_196]
24-13	3335-3344	influence	abstract[196]	new[196]	_	_
24-14	3345-3347	on	abstract[196]	new[196]	_	_
24-15	3348-3355	urinary	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
24-16	3356-3358	pH	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
24-17	3359-3360	,	abstract[196]	new[196]	_	_
24-18	3361-3368	urinary	abstract[196]|event[200]	new[196]|giv[200]	coref	29-4[242_200]
24-19	3369-3373	uric	abstract[196]|abstract|substance[199]|event[200]	new[196]|giv|giv[199]|giv[200]	coref|coref	25-21|25-22[0_199]
24-20	3374-3378	acid	abstract[196]|substance[199]|event[200]	new[196]|giv[199]|giv[200]	_	_
24-21	3379-3388	excretion	abstract[196]|event[200]	new[196]|giv[200]	_	_
24-22	3389-3391	or	abstract[196]	new[196]	_	_
24-23	3392-3397	urate	abstract[196]|abstract|abstract[202]	new[196]|giv|giv[202]	coref	29-8[245_202]
24-24	3398-3407	clearance	abstract[196]|abstract[202]	new[196]|giv[202]	_	_
24-25	3408-3409	.	_	_	_	_

#Text=As the effect of tryptophan on URAT1 might be structurally difficult , tryptophan might have exerted an indirect action against uric acid elevation via its influence on the action of glycine .
25-1	3410-3412	As	_	_	_	_
25-2	3413-3416	the	abstract[203]	new[203]	_	_
25-3	3417-3423	effect	abstract[203]	new[203]	_	_
25-4	3424-3426	of	abstract[203]	new[203]	_	_
25-5	3427-3437	tryptophan	abstract[203]|substance	new[203]|giv	coref	25-13
25-6	3438-3440	on	abstract[203]	new[203]	_	_
25-7	3441-3446	URAT1	abstract[203]|abstract	new[203]|giv	_	_
25-8	3447-3452	might	_	_	_	_
25-9	3453-3455	be	_	_	_	_
25-10	3456-3468	structurally	_	_	_	_
25-11	3469-3478	difficult	_	_	_	_
25-12	3479-3480	,	_	_	_	_
25-13	3481-3491	tryptophan	substance	giv	coref	26-3
25-14	3492-3497	might	_	_	_	_
25-15	3498-3502	have	_	_	_	_
25-16	3503-3510	exerted	_	_	_	_
25-17	3511-3513	an	event[207]	giv[207]	_	_
25-18	3514-3522	indirect	event[207]	giv[207]	_	_
25-19	3523-3529	action	event[207]	giv[207]	_	_
25-20	3530-3537	against	event[207]	giv[207]	_	_
25-21	3538-3542	uric	event[207]|abstract|abstract[210]	giv[207]|giv|giv[210]	coref|coref	26-12|26-12[220_210]
25-22	3543-3547	acid	event[207]|substance|abstract[210]	giv[207]|giv|giv[210]	coref	26-12[219_0]
25-23	3548-3557	elevation	event[207]|abstract[210]	giv[207]|giv[210]	_	_
25-24	3558-3561	via	_	_	_	_
25-25	3562-3565	its	substance|abstract[212]	giv|giv[212]	coref	30-12[252_0]
25-26	3566-3575	influence	abstract[212]	giv[212]	_	_
25-27	3576-3578	on	abstract[212]	giv[212]	_	_
25-28	3579-3582	the	abstract[212]|event[213]	giv[212]|new[213]	_	_
25-29	3583-3589	action	abstract[212]|event[213]	giv[212]|new[213]	_	_
25-30	3590-3592	of	abstract[212]|event[213]	giv[212]|new[213]	_	_
25-31	3593-3600	glycine	abstract[212]|event[213]|substance	giv[212]|new[213]|giv	coref	26-10
25-32	3601-3602	.	_	_	_	_

#Text=Specifically , tryptophan might promote the direct action of glycine against uric acid elevation .
26-1	3603-3615	Specifically	_	_	_	_
26-2	3616-3617	,	_	_	_	_
26-3	3618-3628	tryptophan	substance	giv	coref	27-8
26-4	3629-3634	might	_	_	_	_
26-5	3635-3642	promote	_	_	_	_
26-6	3643-3646	the	event[216]	new[216]	_	_
26-7	3647-3653	direct	event[216]	new[216]	_	_
26-8	3654-3660	action	event[216]	new[216]	_	_
26-9	3661-3663	of	event[216]	new[216]	_	_
26-10	3664-3671	glycine	event[216]|substance	new[216]|giv	coref	27-6
26-11	3672-3679	against	event[216]	new[216]	_	_
26-12	3680-3684	uric	event[216]|abstract|substance[219]|abstract[220]	new[216]|giv|giv[219]|giv[220]	coref|coref	11-8[0_219]|32-20
26-13	3685-3689	acid	event[216]|substance[219]|abstract[220]	new[216]|giv[219]|giv[220]	_	_
26-14	3690-3699	elevation	event[216]|abstract[220]	new[216]|giv[220]	_	_
26-15	3700-3701	.	_	_	_	_

#Text=The maximum serum levels of glycine and tryptophan are achieved within an hour of ingestion , which is followed by rapid decreases as the amino acids are metabolized .
27-1	3702-3705	The	abstract[222]	giv[222]	coref	34-19[307_222]
27-2	3706-3713	maximum	abstract[222]	giv[222]	_	_
27-3	3714-3719	serum	substance|abstract[222]	giv|giv[222]	coref	31-8
27-4	3720-3726	levels	abstract[222]	giv[222]	_	_
27-5	3727-3729	of	abstract[222]	giv[222]	_	_
27-6	3730-3737	glycine	abstract[222]|substance|substance[224]	giv[222]|giv|giv[224]	coref|coref	29-12|30-16[254_224]
27-7	3738-3741	and	abstract[222]|substance[224]	giv[222]|giv[224]	_	_
27-8	3742-3752	tryptophan	abstract[222]|substance[224]|substance	giv[222]|giv[224]|giv	coref	30-18
27-9	3753-3756	are	_	_	_	_
27-10	3757-3765	achieved	_	_	_	_
27-11	3766-3772	within	_	_	_	_
27-12	3773-3775	an	time[226]	new[226]	_	_
27-13	3776-3780	hour	time[226]	new[226]	_	_
27-14	3781-3783	of	time[226]	new[226]	_	_
27-15	3784-3793	ingestion	time[226]|event[227]	new[226]|giv[227]	_	_
27-16	3794-3795	,	time[226]|event[227]	new[226]|giv[227]	_	_
27-17	3796-3801	which	time[226]|event[227]	new[226]|giv[227]	_	_
27-18	3802-3804	is	time[226]|event[227]	new[226]|giv[227]	_	_
27-19	3805-3813	followed	time[226]|event[227]	new[226]|giv[227]	_	_
27-20	3814-3816	by	time[226]|event[227]	new[226]|giv[227]	_	_
27-21	3817-3822	rapid	time[226]|event[227]|event[228]	new[226]|giv[227]|new[228]	_	_
27-22	3823-3832	decreases	time[226]|event[227]|event[228]	new[226]|giv[227]|new[228]	_	_
27-23	3833-3835	as	_	_	_	_
27-24	3836-3839	the	substance[230]	giv[230]	coref	28-17[239_230]
27-25	3840-3845	amino	object|substance[230]	giv|giv[230]	_	_
27-26	3846-3851	acids	substance[230]	giv[230]	_	_
27-27	3852-3855	are	_	_	_	_
27-28	3856-3867	metabolized	_	_	_	_
27-29	3868-3869	.	_	_	_	_

#Text=Glycine metabolizes various end-products , namely glutathione , nucleic acid bases , heme , creatine and bile acids .
28-1	3870-3877	Glycine	_	_	_	_
28-2	3878-3889	metabolizes	_	_	_	_
28-3	3890-3897	various	animal[231]	new[231]	appos	28-6[233_231]
28-4	3898-3910	end-products	animal[231]	new[231]	_	_
28-5	3911-3912	,	_	_	_	_
28-6	3913-3919	namely	substance[232]|animal[233]	new[232]|giv[233]	_	_
28-7	3920-3931	glutathione	substance[232]|animal[233]	new[232]|giv[233]	_	_
28-8	3932-3933	,	animal[233]	giv[233]	_	_
28-9	3934-3941	nucleic	animal[233]|substance[234]|abstract[235]	giv[233]|giv[234]|new[235]	coref	32-20[279_0]
28-10	3942-3946	acid	animal[233]|substance[234]|abstract[235]	giv[233]|giv[234]|new[235]	_	_
28-11	3947-3952	bases	animal[233]|abstract[235]	giv[233]|new[235]	_	_
28-12	3953-3954	,	animal[233]	giv[233]	_	_
28-13	3955-3959	heme	animal[233]|substance	giv[233]|new	_	_
28-14	3960-3961	,	animal[233]	giv[233]	_	_
28-15	3962-3970	creatine	animal[233]|substance	giv[233]|new	coref	29-27
28-16	3971-3974	and	animal[233]	giv[233]	_	_
28-17	3975-3979	bile	animal[233]|object|substance[239]	giv[233]|new|giv[239]	_	_
28-18	3980-3985	acids	animal[233]|substance[239]	giv[233]|giv[239]	_	_
28-19	3986-3987	.	_	_	_	_

#Text=The increases in urinary creatinine excretion and creatinine clearance following the glycine challenge suggest that glycine might be partially absorbed back and metabolized to creatinine through creatine .
29-1	3988-3991	The	event[240]	new[240]	coref	31-4[261_240]
29-2	3992-4001	increases	event[240]	new[240]	_	_
29-3	4002-4004	in	event[240]	new[240]	_	_
29-4	4005-4012	urinary	event[240]|event[242]|abstract[243]	new[240]|giv[242]|giv[243]	coref	31-12[266_242]
29-5	4013-4023	creatinine	event[240]|substance|event[242]|abstract[243]	new[240]|new|giv[242]|giv[243]	coref	29-8
29-6	4024-4033	excretion	event[240]|event[242]|abstract[243]	new[240]|giv[242]|giv[243]	_	_
29-7	4034-4037	and	event[240]|abstract[243]	new[240]|giv[243]	_	_
29-8	4038-4048	creatinine	event[240]|abstract[243]|substance|abstract[245]	new[240]|giv[243]|giv|giv[245]	coref	29-25
29-9	4049-4058	clearance	event[240]|abstract[243]|abstract[245]	new[240]|giv[243]|giv[245]	_	_
29-10	4059-4068	following	event[240]|abstract[243]|abstract[245]	new[240]|giv[243]|giv[245]	_	_
29-11	4069-4072	the	event[240]|abstract[243]|abstract[245]|event[247]	new[240]|giv[243]|giv[245]|new[247]	_	_
29-12	4073-4080	glycine	event[240]|abstract[243]|abstract[245]|substance|event[247]	new[240]|giv[243]|giv[245]|giv|new[247]	coref	29-16
29-13	4081-4090	challenge	event[240]|abstract[243]|abstract[245]|event[247]	new[240]|giv[243]|giv[245]|new[247]	_	_
29-14	4091-4098	suggest	_	_	_	_
29-15	4099-4103	that	_	_	_	_
29-16	4104-4111	glycine	substance	giv	coref	30-16
29-17	4112-4117	might	_	_	_	_
29-18	4118-4120	be	_	_	_	_
29-19	4121-4130	partially	_	_	_	_
29-20	4131-4139	absorbed	_	_	_	_
29-21	4140-4144	back	_	_	_	_
29-22	4145-4148	and	_	_	_	_
29-23	4149-4160	metabolized	_	_	_	_
29-24	4161-4163	to	_	_	_	_
29-25	4164-4174	creatinine	substance	giv	coref	30-29
29-26	4175-4182	through	_	_	_	_
29-27	4183-4191	creatine	substance	giv	_	_
29-28	4192-4193	.	_	_	_	_

#Text=Conversely , these urinary parameters did not change in response to the simultaneous supplementation with glycine and tryptophan , suggesting the suppression of the conversion of glycine to creatinine by tryptophan .
30-1	4194-4204	Conversely	_	_	_	_
30-2	4205-4206	,	_	_	_	_
30-3	4207-4212	these	abstract[251]	new[251]	_	_
30-4	4213-4220	urinary	abstract[251]	new[251]	_	_
30-5	4221-4231	parameters	abstract[251]	new[251]	_	_
30-6	4232-4235	did	_	_	_	_
30-7	4236-4239	not	_	_	_	_
30-8	4240-4246	change	_	_	_	_
30-9	4247-4249	in	_	_	_	_
30-10	4250-4258	response	_	_	_	_
30-11	4259-4261	to	_	_	_	_
30-12	4262-4265	the	substance[252]	giv[252]	coref	31-21[267_252]
30-13	4266-4278	simultaneous	substance[252]	giv[252]	_	_
30-14	4279-4294	supplementation	substance[252]	giv[252]	_	_
30-15	4295-4299	with	substance[252]	giv[252]	_	_
30-16	4300-4307	glycine	substance[252]|substance|substance[254]	giv[252]|giv|giv[254]	coref|coref	30-27[258_0]|31-23[269_254]
30-17	4308-4311	and	substance[252]|substance[254]	giv[252]|giv[254]	_	_
30-18	4312-4322	tryptophan	substance[252]|substance[254]|substance	giv[252]|giv[254]|giv	coref	30-31
30-19	4323-4324	,	_	_	_	_
30-20	4325-4335	suggesting	_	_	_	_
30-21	4336-4339	the	event[256]	new[256]	_	_
30-22	4340-4351	suppression	event[256]	new[256]	_	_
30-23	4352-4354	of	event[256]	new[256]	_	_
30-24	4355-4358	the	event[256]|event[257]	new[256]|new[257]	_	_
30-25	4359-4369	conversion	event[256]|event[257]	new[256]|new[257]	_	_
30-26	4370-4372	of	event[256]|event[257]	new[256]|new[257]	_	_
30-27	4373-4380	glycine	event[256]|event[257]|substance[258]	new[256]|new[257]|giv[258]	coref	31-13[0_258]
30-28	4381-4383	to	event[256]|event[257]|substance[258]	new[256]|new[257]|giv[258]	_	_
30-29	4384-4394	creatinine	event[256]|event[257]|substance[258]|substance	new[256]|new[257]|giv[258]|giv	_	_
30-30	4395-4397	by	_	_	_	_
30-31	4398-4408	tryptophan	substance	giv	coref	31-25
30-32	4409-4410	.	_	_	_	_

#Text=In fact , the increases in the serum glycine/creatinine ratio and urinary glycine excretion were more pronounced in response to supplementation with glycine and tryptophan than with glycine alone .
31-1	4411-4413	In	_	_	_	_
31-2	4414-4418	fact	_	_	_	_
31-3	4419-4420	,	_	_	_	_
31-4	4421-4424	the	event[261]	giv[261]	_	_
31-5	4425-4434	increases	event[261]	giv[261]	_	_
31-6	4435-4437	in	event[261]	giv[261]	_	_
31-7	4438-4441	the	event[261]|abstract[264]	giv[261]|new[264]	_	_
31-8	4442-4447	serum	event[261]|substance|abstract[264]	giv[261]|giv|new[264]	coref	34-19
31-9	4448-4466	glycine/creatinine	event[261]|abstract|abstract[264]	giv[261]|new|new[264]	_	_
31-10	4467-4472	ratio	event[261]|abstract[264]	giv[261]|new[264]	_	_
31-11	4473-4476	and	event[261]	giv[261]	_	_
31-12	4477-4484	urinary	event[261]|event[266]	giv[261]|giv[266]	coref	32-20[280_266]
31-13	4485-4492	glycine	event[261]|substance|event[266]	giv[261]|giv|giv[266]	coref	31-23
31-14	4493-4502	excretion	event[261]|event[266]	giv[261]|giv[266]	_	_
31-15	4503-4507	were	_	_	_	_
31-16	4508-4512	more	_	_	_	_
31-17	4513-4523	pronounced	_	_	_	_
31-18	4524-4526	in	_	_	_	_
31-19	4527-4535	response	_	_	_	_
31-20	4536-4538	to	_	_	_	_
31-21	4539-4554	supplementation	substance[267]	giv[267]	coref	35-25[317_267]
31-22	4555-4559	with	substance[267]	giv[267]	_	_
31-23	4560-4567	glycine	substance[267]|substance|substance[269]	giv[267]|giv|giv[269]	coref|coref	31-28[271_0]|33-43[295_269]
31-24	4568-4571	and	substance[267]|substance[269]	giv[267]|giv[269]	_	_
31-25	4572-4582	tryptophan	substance[267]|substance[269]|substance	giv[267]|giv[269]|giv	coref	32-13
31-26	4583-4587	than	substance[267]	giv[267]	_	_
31-27	4588-4592	with	substance[267]	giv[267]	_	_
31-28	4593-4600	glycine	substance[267]|substance[271]	giv[267]|giv[271]	coref	32-18[0_271]
31-29	4601-4606	alone	substance[267]|substance[271]	giv[267]|giv[271]	_	_
31-30	4607-4608	.	_	_	_	_

#Text=Further studies are required to clarify the mechanism underlying the contribution of tryptophan to the effects of glycine on uric acid excretion .
32-1	4609-4616	Further	abstract[272]	giv[272]	coref	35-1[308_272]
32-2	4617-4624	studies	abstract[272]	giv[272]	_	_
32-3	4625-4628	are	_	_	_	_
32-4	4629-4637	required	_	_	_	_
32-5	4638-4640	to	_	_	_	_
32-6	4641-4648	clarify	_	_	_	_
32-7	4649-4652	the	abstract[273]	new[273]	_	_
32-8	4653-4662	mechanism	abstract[273]	new[273]	_	_
32-9	4663-4673	underlying	abstract[273]	new[273]	_	_
32-10	4674-4677	the	abstract[273]|abstract[274]	new[273]|new[274]	_	_
32-11	4678-4690	contribution	abstract[273]|abstract[274]	new[273]|new[274]	_	_
32-12	4691-4693	of	abstract[273]|abstract[274]	new[273]|new[274]	_	_
32-13	4694-4704	tryptophan	abstract[273]|abstract[274]|substance	new[273]|new[274]|giv	coref	35-27
32-14	4705-4707	to	abstract[273]	new[273]	_	_
32-15	4708-4711	the	abstract[273]|abstract[276]	new[273]|new[276]	_	_
32-16	4712-4719	effects	abstract[273]|abstract[276]	new[273]|new[276]	_	_
32-17	4720-4722	of	abstract[273]|abstract[276]	new[273]|new[276]	_	_
32-18	4723-4730	glycine	abstract[273]|abstract[276]|substance	new[273]|new[276]|giv	coref	33-43[294_0]
32-19	4731-4733	on	abstract[273]|abstract[276]	new[273]|new[276]	_	_
32-20	4734-4738	uric	abstract[273]|abstract[276]|abstract|substance[279]|event[280]	new[273]|new[276]|giv|giv[279]|giv[280]	coref|coref	34-20|34-20[306_279]
32-21	4739-4743	acid	abstract[273]|abstract[276]|substance[279]|event[280]	new[273]|new[276]|giv[279]|giv[280]	_	_
32-22	4744-4753	excretion	abstract[273]|abstract[276]|event[280]	new[273]|new[276]|giv[280]	_	_
32-23	4754-4755	.	_	_	_	_

#Text=Among the limitations in the current clinical study , the modest sample size ( n = 16 ) might have reduced the statistical power and increased the risk of type II error , particularly regarding the statistical differences in multiple comparisons between the glycine and glycine + tryptophan groups .
33-1	4756-4761	Among	_	_	_	_
33-2	4762-4765	the	abstract[281]	new[281]	_	_
33-3	4766-4777	limitations	abstract[281]	new[281]	_	_
33-4	4778-4780	in	abstract[281]	new[281]	_	_
33-5	4781-4784	the	abstract[281]|abstract[282]	new[281]|giv[282]	coref	34-3[299_282]
33-6	4785-4792	current	abstract[281]|abstract[282]	new[281]|giv[282]	_	_
33-7	4793-4801	clinical	abstract[281]|abstract[282]	new[281]|giv[282]	_	_
33-8	4802-4807	study	abstract[281]|abstract[282]	new[281]|giv[282]	_	_
33-9	4808-4809	,	_	_	_	_
33-10	4810-4813	the	abstract[284]	new[284]	_	_
33-11	4814-4820	modest	abstract[284]	new[284]	_	_
33-12	4821-4827	sample	object|abstract[284]	new|new[284]	_	_
33-13	4828-4832	size	abstract[284]	new[284]	_	_
33-14	4833-4834	(	_	_	_	_
33-15	4835-4836	n	abstract	new	_	_
33-16	4837-4838	=	_	_	_	_
33-17	4839-4841	16	abstract	new	_	_
33-18	4842-4843	)	_	_	_	_
33-19	4844-4849	might	_	_	_	_
33-20	4850-4854	have	_	_	_	_
33-21	4855-4862	reduced	_	_	_	_
33-22	4863-4866	the	abstract[287]	new[287]	_	_
33-23	4867-4878	statistical	abstract[287]	new[287]	_	_
33-24	4879-4884	power	abstract[287]	new[287]	_	_
33-25	4885-4888	and	_	_	_	_
33-26	4889-4898	increased	_	_	_	_
33-27	4899-4902	the	abstract[288]	new[288]	_	_
33-28	4903-4907	risk	abstract[288]	new[288]	_	_
33-29	4908-4910	of	abstract[288]	new[288]	_	_
33-30	4911-4915	type	abstract[288]|abstract[289]|abstract[291]	new[288]|new[289]|new[291]	_	_
33-31	4916-4918	II	abstract[288]|abstract[289]|person|abstract[291]	new[288]|new[289]|new|new[291]	_	_
33-32	4919-4924	error	abstract[288]|abstract[291]	new[288]|new[291]	_	_
33-33	4925-4926	,	_	_	_	_
33-34	4927-4939	particularly	abstract[292]	new[292]	coref	34-16[303_292]
33-35	4940-4949	regarding	abstract[292]	new[292]	_	_
33-36	4950-4953	the	abstract[292]	new[292]	_	_
33-37	4954-4965	statistical	abstract[292]	new[292]	_	_
33-38	4966-4977	differences	abstract[292]	new[292]	_	_
33-39	4978-4980	in	abstract[292]	new[292]	_	_
33-40	4981-4989	multiple	abstract[292]|abstract[293]	new[292]|new[293]	_	_
33-41	4990-5001	comparisons	abstract[292]|abstract[293]	new[292]|new[293]	_	_
33-42	5002-5009	between	abstract[292]|abstract[293]	new[292]|new[293]	_	_
33-43	5010-5013	the	abstract[292]|abstract[293]|substance[294]|substance[295]|person[298]	new[292]|new[293]|giv[294]|giv[295]|new[298]	coref|coref	33-46[0_294]|33-46[297_295]
33-44	5014-5021	glycine	abstract[292]|abstract[293]|substance[294]|substance[295]|person[298]	new[292]|new[293]|giv[294]|giv[295]|new[298]	_	_
33-45	5022-5025	and	abstract[292]|abstract[293]|substance[295]|person[298]	new[292]|new[293]|giv[295]|new[298]	_	_
33-46	5026-5033	glycine	abstract[292]|abstract[293]|substance[295]|substance|substance[297]|person[298]	new[292]|new[293]|giv[295]|giv|giv[297]|new[298]	coref|coref	35-25|35-25[315_297]
33-47	5034-5035	+	abstract[292]|abstract[293]|substance[295]|substance[297]|person[298]	new[292]|new[293]|giv[295]|giv[297]|new[298]	_	_
33-48	5036-5046	tryptophan	abstract[292]|abstract[293]|substance[295]|substance[297]|person[298]	new[292]|new[293]|giv[295]|giv[297]|new[298]	_	_
33-49	5047-5053	groups	abstract[292]|abstract[293]|person[298]	new[292]|new[293]|new[298]	_	_
33-50	5054-5055	.	_	_	_	_

#Text=Furthermore , the current study included only male subjects because of the known effects of sex differences on serum uric acid levels .
34-1	5056-5067	Furthermore	_	_	_	_
34-2	5068-5069	,	_	_	_	_
34-3	5070-5073	the	abstract[299]	giv[299]	_	_
34-4	5074-5081	current	abstract[299]	giv[299]	_	_
34-5	5082-5087	study	abstract[299]	giv[299]	_	_
34-6	5088-5096	included	_	_	_	_
34-7	5097-5101	only	animal[300]	new[300]	_	_
34-8	5102-5106	male	animal[300]	new[300]	_	_
34-9	5107-5115	subjects	animal[300]	new[300]	_	_
34-10	5116-5123	because	_	_	_	_
34-11	5124-5126	of	_	_	_	_
34-12	5127-5130	the	abstract[301]	new[301]	_	_
34-13	5131-5136	known	abstract[301]	new[301]	_	_
34-14	5137-5144	effects	abstract[301]	new[301]	_	_
34-15	5145-5147	of	abstract[301]	new[301]	_	_
34-16	5148-5151	sex	abstract[301]|event|abstract[303]	new[301]|new|giv[303]	coref	35-15[311_303]
34-17	5152-5163	differences	abstract[301]|abstract[303]	new[301]|giv[303]	_	_
34-18	5164-5166	on	abstract[301]	new[301]	_	_
34-19	5167-5172	serum	abstract[301]|substance|abstract[307]	new[301]|giv|giv[307]	_	_
34-20	5173-5177	uric	abstract[301]|abstract|substance[306]|abstract[307]	new[301]|giv|giv[306]|giv[307]	_	_
34-21	5178-5182	acid	abstract[301]|substance[306]|abstract[307]	new[301]|giv[306]|giv[307]	_	_
34-22	5183-5189	levels	abstract[301]|abstract[307]	new[301]|giv[307]	_	_
34-23	5190-5191	.	_	_	_	_

#Text=Further studies are therefore needed , although our preliminary findings suggested that there were no effective differences between males and females in response to glycine and tryptophan supplementation ( data not shown ) .
35-1	5192-5199	Further	abstract[308]	giv[308]	_	_
35-2	5200-5207	studies	abstract[308]	giv[308]	_	_
35-3	5208-5211	are	_	_	_	_
35-4	5212-5221	therefore	_	_	_	_
35-5	5222-5228	needed	_	_	_	_
35-6	5229-5230	,	_	_	_	_
35-7	5231-5239	although	_	_	_	_
35-8	5240-5243	our	person|abstract[310]	acc|new[310]	_	_
35-9	5244-5255	preliminary	abstract[310]	new[310]	_	_
35-10	5256-5264	findings	abstract[310]	new[310]	_	_
35-11	5265-5274	suggested	_	_	_	_
35-12	5275-5279	that	_	_	_	_
35-13	5280-5285	there	_	_	_	_
35-14	5286-5290	were	_	_	_	_
35-15	5291-5293	no	abstract[311]	giv[311]	_	_
35-16	5294-5303	effective	abstract[311]	giv[311]	_	_
35-17	5304-5315	differences	abstract[311]	giv[311]	_	_
35-18	5316-5323	between	abstract[311]	giv[311]	_	_
35-19	5324-5329	males	abstract[311]|animal	giv[311]|new	_	_
35-20	5330-5333	and	abstract[311]	giv[311]	_	_
35-21	5334-5341	females	abstract[311]|person	giv[311]|new	_	_
35-22	5342-5344	in	abstract[311]	giv[311]	_	_
35-23	5345-5353	response	abstract[311]	giv[311]	_	_
35-24	5354-5356	to	abstract[311]	giv[311]	_	_
35-25	5357-5364	glycine	abstract[311]|substance|substance[315]|substance[317]	giv[311]|giv|giv[315]|giv[317]	_	_
35-26	5365-5368	and	abstract[311]|substance[315]|substance[317]	giv[311]|giv[315]|giv[317]	_	_
35-27	5369-5379	tryptophan	abstract[311]|substance[315]|substance|substance[317]	giv[311]|giv[315]|giv|giv[317]	_	_
35-28	5380-5395	supplementation	abstract[311]|substance[317]	giv[311]|giv[317]	_	_
35-29	5396-5397	(	_	_	_	_
35-30	5398-5402	data	abstract[318]	new[318]	_	_
35-31	5403-5406	not	abstract[318]	new[318]	_	_
35-32	5407-5412	shown	abstract[318]	new[318]	_	_
35-33	5413-5414	)	_	_	_	_
35-34	5415-5416	.	_	_	_	_
